Stock Events

Stock Events

Design Therapeutics 

$15.53
17
+$0.26+1.7% 17:19 Today

Statistics

Day High
16.12
Day Low
15.3
52W High
17.25
52W Low
4.68
Volume
305,111
Avg. Volume
785,520
Mkt Cap
971.89M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.34
-0.31
-0.27
-0.24
Expected EPS
-0.344286
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-69.79MNet Income

Analyst Ratings

14.50Average Price Target
The highest estimate is 15.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DSGN. It's not an investment recommendation.
Microsoft
4
MSFT
NVIDIA
4
NVDA
AMD
4
AMD
Intel
4
INTC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, including genetic disorders, directly competing with Design Therapeutics' focus on gene-targeted therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is a leader in the development of gene editing technologies, which are central to Design Therapeutics' approach to treating genetic diseases.
Beam Therapeutics
BEAM
Mkt Cap2.76B
Beam Therapeutics uses base editing, a form of gene editing, to develop precision genetic medicines, competing in the same space as Design Therapeutics.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is a pioneer in CRISPR/Cas9 technology for the development of gene editing treatments, making it a direct competitor.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine focuses on discovering and developing gene editing therapies using CRISPR technology, similar to Design Therapeutics' gene-targeted approach.
PTC Therapeutics
PTCT
Mkt Cap5.98B
PTC Therapeutics operates in the field of genetic disorders by targeting the underlying causes of certain genetic diseases, similar to Design Therapeutics' mission.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics is involved in the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, aligning with Design Therapeutics' focus.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.61B
Ultragenyx Pharmaceutical focuses on developing treatments for rare and ultra-rare genetic diseases, directly competing with Design Therapeutics in targeting genetic disorders.

About

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Show more...
CEO
Pratik Shah
Employees
55
Country
United States
ISIN
US25056L1035

Listings

XNAS
US
DSGN
BOATS
BOATS
DSGN.BOATS

0 Comments

Share your thoughts

FAQ

What is Design Therapeutics stock price today?▼
The current price of DSGN is $15.53 USD — it has increased by +1.7% in the past 24 hours. Watch Design Therapeutics stock price performance more closely on the chart.
What is Design Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Design Therapeutics stocks are traded under the ticker DSGN.
Is Design Therapeutics stock price growing?▼
DSGN stock has risen by +5.8% compared to the previous week, the month change is a +23.39% rise, over the last year Design Therapeutics has showed a +200% increase.
What is Design Therapeutics market cap?▼
Today Design Therapeutics has the market capitalization of 971.89M
When is the next Design Therapeutics earnings date?▼
Design Therapeutics is going to release the next earnings report on November 11, 2026.
What were Design Therapeutics earnings last quarter?▼
DSGN earnings for the last quarter are -0.32 USD per share, whereas the estimation was -0.34 USD resulting in a +7.05% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Design Therapeutics revenue for the last year?▼
Design Therapeutics revenue for the last year amounts to 0 USD.
What is Design Therapeutics net income for the last year?▼
DSGN net income for the last year is -69.79M USD.
How many employees does Design Therapeutics have?▼
As of August 19, 2026, the company has 55 employees.
In which sector is Design Therapeutics located?▼
Design Therapeutics operates in the Health & Wellness sector.
When did Design Therapeutics complete a stock split?▼
Design Therapeutics has not had any recent stock splits.
Where is Design Therapeutics headquartered?▼
Design Therapeutics is headquartered in CARLSBAD, United States.